Upon joining the study, you will attend an initial visit. During this visit, your eligibility for the trial will be confirmed based on specific criteria, such as your diagnosis of relapsing forms of multiple sclerosis and your medical history.

You will undergo a series of assessments, including a review of your medical history and a physical examination. This visit will help establish a baseline for your health status before starting the trial.

After the initial assessments, you will be randomly assigned to one of the treatment groups. This means you will either receive the study medication frexalimab or the comparison medication teriflunomide.

The assignment is random to ensure that the study results are unbiased and reliable.

If you are assigned to the frexalimab group, you will receive the medication through an intravenous infusion. The frequency and duration of these infusions will be explained to you by the study team.

If you are assigned to the teriflunomide group, you will take a 14 mg film-coated tablet orally once daily.

Throughout the treatment phase, you will have regular visits to monitor your health and the effects of the medication. These visits will include physical exams, blood tests, and other necessary assessments.

During the trial, your health will be closely monitored. This includes regular check-ups and assessments to track any changes in your condition.

You may also undergo MRI scans to evaluate the effects of the treatment on your brain and to detect any new or enlarging lesions.

At the end of the study period, you will have a final visit. This visit will include a comprehensive assessment of your health and a review of your experience during the trial.

The study team will discuss the next steps with you, including any follow-up care or additional treatments that may be necessary.